The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Biosimilar Insulin Market Research Report 2025
Synopsis
Biosimilar insulin is a biological copy of an original insulin and there is increasing interest in developing and using them. Biosimilar insulins (hereafter called biosimilars or follow-on biologics) are designed to be highly similar to the original, or reference, insulin product described in a patent. They are analogous to generic versions of small-molecule drugs and are developed by companies other than the reference product's patent holder. Producers of biosimilars use manufacturing techniques that are similar, but likely not identical to, those used by the original patent holder. Thus, although a biosimilar and its reference insulin product will have the same amino acid sequence, they may differ slightly in their more subtle molecular characteristics and clinical profiles.
The global Biosimilar Insulin market was valued at US$ 2558 million in 2023 and is anticipated to reach US$ 6548.3 million by 2030, witnessing a CAGR of 14.2% during the forecast period 2024-2030.
Global Biosimilar Insulin key players include Biocon, Gan&Lee, Wockhardt, Eli Lilly, Sanofi etc. Global top three players hold a share over 70%. India is the largest market, with a share about 30%, followed by Southeast Asia and China, both have a share about 40 percent
This report aims to provide a comprehensive presentation of the global market for Biosimilar Insulin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilar Insulin.
Report Scope
The Biosimilar Insulin market size, estimations, and forecasts are provided in terms of sales volume (K Unit) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Biosimilar Insulin market comprehensively. Regional market sizes, concerning products by Type, by Distribution Channel, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biosimilar Insulin manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Distribution Channel, and by regions.
Market Segmentation
By Company
Eli Lilly
Sanofi
Gan&Lee
Tonghua Dongbao
United Laboratory
Geropharm
Biocon
Wockhardt
Segment by Type
Biosimilar Insulin Glargine
Biosimilar Insulin Lispro
Other
Segment by Distribution Channel
Hospital
Retail Pharmacy
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Distribution Channel, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Biosimilar Insulin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Biosimilar Insulin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Distribution Channel, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Biosimilar insulin is a biological copy of an original insulin and there is increasing interest in developing and using them. Biosimilar insulins (hereafter called biosimilars or follow-on biologics) are designed to be highly similar to the original, or reference, insulin product described in a patent. They are analogous to generic versions of small-molecule drugs and are developed by companies other than the reference product's patent holder. Producers of biosimilars use manufacturing techniques that are similar, but likely not identical to, those used by the original patent holder. Thus, although a biosimilar and its reference insulin product will have the same amino acid sequence, they may differ slightly in their more subtle molecular characteristics and clinical profiles.
The global Biosimilar Insulin market was valued at US$ 2558 million in 2023 and is anticipated to reach US$ 6548.3 million by 2030, witnessing a CAGR of 14.2% during the forecast period 2024-2030.
Global Biosimilar Insulin key players include Biocon, Gan&Lee, Wockhardt, Eli Lilly, Sanofi etc. Global top three players hold a share over 70%. India is the largest market, with a share about 30%, followed by Southeast Asia and China, both have a share about 40 percent
This report aims to provide a comprehensive presentation of the global market for Biosimilar Insulin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilar Insulin.
Report Scope
The Biosimilar Insulin market size, estimations, and forecasts are provided in terms of sales volume (K Unit) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Biosimilar Insulin market comprehensively. Regional market sizes, concerning products by Type, by Distribution Channel, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biosimilar Insulin manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Distribution Channel, and by regions.
Market Segmentation
By Company
Eli Lilly
Sanofi
Gan&Lee
Tonghua Dongbao
United Laboratory
Geropharm
Biocon
Wockhardt
Segment by Type
Biosimilar Insulin Glargine
Biosimilar Insulin Lispro
Other
Segment by Distribution Channel
Hospital
Retail Pharmacy
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Distribution Channel, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Biosimilar Insulin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Biosimilar Insulin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Distribution Channel, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Biosimilar Insulin Market Overview
1.1 Product Overview and Scope of Biosimilar Insulin
1.2 Biosimilar Insulin Segment by Type
1.2.1 Global Biosimilar Insulin Market Value Comparison by Type (2024-2030)
1.2.2 Biosimilar Insulin Glargine
1.2.3 Biosimilar Insulin Lispro
1.2.4 Other
1.3 Biosimilar Insulin Segment by Distribution Channel
1.3.1 Global Biosimilar Insulin Market Value by Distribution Channel: (2024-2030)
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Others
1.4 Global Biosimilar Insulin Market Size Estimates and Forecasts
1.4.1 Global Biosimilar Insulin Revenue 2019-2030
1.4.2 Global Biosimilar Insulin Sales 2019-2030
1.4.3 Global Biosimilar Insulin Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Biosimilar Insulin Market Competition by Manufacturers
2.1 Global Biosimilar Insulin Sales Market Share by Manufacturers (2019-2024)
2.2 Global Biosimilar Insulin Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Biosimilar Insulin Average Price by Manufacturers (2019-2024)
2.4 Global Biosimilar Insulin Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Biosimilar Insulin, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Biosimilar Insulin, Product Type & Application
2.7 Biosimilar Insulin Market Competitive Situation and Trends
2.7.1 Biosimilar Insulin Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Biosimilar Insulin Players Market Share by Revenue
2.7.3 Global Biosimilar Insulin Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Biosimilar Insulin Retrospective Market Scenario by Region
3.1 Global Biosimilar Insulin Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Biosimilar Insulin Global Biosimilar Insulin Sales by Region: 2019-2030
3.2.1 Global Biosimilar Insulin Sales by Region: 2019-2024
3.2.2 Global Biosimilar Insulin Sales by Region: 2025-2030
3.3 Global Biosimilar Insulin Global Biosimilar Insulin Revenue by Region: 2019-2030
3.3.1 Global Biosimilar Insulin Revenue by Region: 2019-2024
3.3.2 Global Biosimilar Insulin Revenue by Region: 2025-2030
3.4 North America Biosimilar Insulin Market Facts & Figures by Country
3.4.1 North America Biosimilar Insulin Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Biosimilar Insulin Sales by Country (2019-2030)
3.4.3 North America Biosimilar Insulin Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Biosimilar Insulin Market Facts & Figures by Country
3.5.1 Europe Biosimilar Insulin Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Biosimilar Insulin Sales by Country (2019-2030)
3.5.3 Europe Biosimilar Insulin Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Biosimilar Insulin Market Facts & Figures by Country
3.6.1 Asia Pacific Biosimilar Insulin Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Biosimilar Insulin Sales by Country (2019-2030)
3.6.3 Asia Pacific Biosimilar Insulin Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Biosimilar Insulin Market Facts & Figures by Country
3.7.1 Latin America Biosimilar Insulin Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Biosimilar Insulin Sales by Country (2019-2030)
3.7.3 Latin America Biosimilar Insulin Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Biosimilar Insulin Market Facts & Figures by Country
3.8.1 Middle East and Africa Biosimilar Insulin Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Biosimilar Insulin Sales by Country (2019-2030)
3.8.3 Middle East and Africa Biosimilar Insulin Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Biosimilar Insulin Sales by Type (2019-2030)
4.1.1 Global Biosimilar Insulin Sales by Type (2019-2024)
4.1.2 Global Biosimilar Insulin Sales by Type (2025-2030)
4.1.3 Global Biosimilar Insulin Sales Market Share by Type (2019-2030)
4.2 Global Biosimilar Insulin Revenue by Type (2019-2030)
4.2.1 Global Biosimilar Insulin Revenue by Type (2019-2024)
4.2.2 Global Biosimilar Insulin Revenue by Type (2025-2030)
4.2.3 Global Biosimilar Insulin Revenue Market Share by Type (2019-2030)
4.3 Global Biosimilar Insulin Price by Type (2019-2030)
5 Segment by Distribution Channel
5.1 Global Biosimilar Insulin Sales by Distribution Channel (2019-2030)
5.1.1 Global Biosimilar Insulin Sales by Distribution Channel (2019-2024)
5.1.2 Global Biosimilar Insulin Sales by Distribution Channel (2025-2030)
5.1.3 Global Biosimilar Insulin Sales Market Share by Distribution Channel (2019-2030)
5.2 Global Biosimilar Insulin Revenue by Distribution Channel (2019-2030)
5.2.1 Global Biosimilar Insulin Revenue by Distribution Channel (2019-2024)
5.2.2 Global Biosimilar Insulin Revenue by Distribution Channel (2025-2030)
5.2.3 Global Biosimilar Insulin Revenue Market Share by Distribution Channel (2019-2030)
5.3 Global Biosimilar Insulin Price by Distribution Channel (2019-2030)
6 Key Companies Profiled
6.1 Eli Lilly
6.1.1 Eli Lilly Corporation Information
6.1.2 Eli Lilly Description and Business Overview
6.1.3 Eli Lilly Biosimilar Insulin Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Eli Lilly Biosimilar Insulin Product Portfolio
6.1.5 Eli Lilly Recent Developments/Updates
6.2 Sanofi
6.2.1 Sanofi Corporation Information
6.2.2 Sanofi Description and Business Overview
6.2.3 Sanofi Biosimilar Insulin Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Sanofi Biosimilar Insulin Product Portfolio
6.2.5 Sanofi Recent Developments/Updates
6.3 Gan&Lee
6.3.1 Gan&Lee Corporation Information
6.3.2 Gan&Lee Description and Business Overview
6.3.3 Gan&Lee Biosimilar Insulin Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Gan&Lee Biosimilar Insulin Product Portfolio
6.3.5 Gan&Lee Recent Developments/Updates
6.4 Tonghua Dongbao
6.4.1 Tonghua Dongbao Corporation Information
6.4.2 Tonghua Dongbao Description and Business Overview
6.4.3 Tonghua Dongbao Biosimilar Insulin Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Tonghua Dongbao Biosimilar Insulin Product Portfolio
6.4.5 Tonghua Dongbao Recent Developments/Updates
6.5 United Laboratory
6.5.1 United Laboratory Corporation Information
6.5.2 United Laboratory Description and Business Overview
6.5.3 United Laboratory Biosimilar Insulin Sales, Revenue and Gross Margin (2019-2024)
6.5.4 United Laboratory Biosimilar Insulin Product Portfolio
6.5.5 United Laboratory Recent Developments/Updates
6.6 Geropharm
6.6.1 Geropharm Corporation Information
6.6.2 Geropharm Description and Business Overview
6.6.3 Geropharm Biosimilar Insulin Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Geropharm Biosimilar Insulin Product Portfolio
6.6.5 Geropharm Recent Developments/Updates
6.7 Biocon
6.6.1 Biocon Corporation Information
6.6.2 Biocon Description and Business Overview
6.6.3 Biocon Biosimilar Insulin Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Biocon Biosimilar Insulin Product Portfolio
6.7.5 Biocon Recent Developments/Updates
6.8 Wockhardt
6.8.1 Wockhardt Corporation Information
6.8.2 Wockhardt Description and Business Overview
6.8.3 Wockhardt Biosimilar Insulin Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Wockhardt Biosimilar Insulin Product Portfolio
6.8.5 Wockhardt Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Biosimilar Insulin Industry Chain Analysis
7.2 Biosimilar Insulin Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Biosimilar Insulin Production Mode & Process
7.4 Biosimilar Insulin Sales and Marketing
7.4.1 Biosimilar Insulin Sales Channels
7.4.2 Biosimilar Insulin Distributors
7.5 Biosimilar Insulin Customers
8 Biosimilar Insulin Market Dynamics
8.1 Biosimilar Insulin Industry Trends
8.2 Biosimilar Insulin Market Drivers
8.3 Biosimilar Insulin Market Challenges
8.4 Biosimilar Insulin Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Biosimilar Insulin Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Biosimilar Insulin Market Value Comparison by Distribution Channel (2024-2030) & (US$ Million)
Table 3. Global Biosimilar Insulin Market Competitive Situation by Manufacturers in 2023
Table 4. Global Biosimilar Insulin Sales (K Unit) of Key Manufacturers (2019-2024)
Table 5. Global Biosimilar Insulin Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Biosimilar Insulin Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Biosimilar Insulin Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Biosimilar Insulin Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Biosimilar Insulin, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Biosimilar Insulin, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Biosimilar Insulin, Product Type & Application
Table 12. Global Key Manufacturers of Biosimilar Insulin, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Biosimilar Insulin by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosimilar Insulin as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Biosimilar Insulin Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Biosimilar Insulin Sales by Region (2019-2024) & (K Unit)
Table 18. Global Biosimilar Insulin Sales Market Share by Region (2019-2024)
Table 19. Global Biosimilar Insulin Sales by Region (2025-2030) & (K Unit)
Table 20. Global Biosimilar Insulin Sales Market Share by Region (2025-2030)
Table 21. Global Biosimilar Insulin Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Biosimilar Insulin Revenue Market Share by Region (2019-2024)
Table 23. Global Biosimilar Insulin Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Biosimilar Insulin Revenue Market Share by Region (2025-2030)
Table 25. North America Biosimilar Insulin Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Biosimilar Insulin Sales by Country (2019-2024) & (K Unit)
Table 27. North America Biosimilar Insulin Sales by Country (2025-2030) & (K Unit)
Table 28. North America Biosimilar Insulin Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Biosimilar Insulin Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Biosimilar Insulin Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Biosimilar Insulin Sales by Country (2019-2024) & (K Unit)
Table 32. Europe Biosimilar Insulin Sales by Country (2025-2030) & (K Unit)
Table 33. Europe Biosimilar Insulin Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Biosimilar Insulin Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Biosimilar Insulin Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Biosimilar Insulin Sales by Region (2019-2024) & (K Unit)
Table 37. Asia Pacific Biosimilar Insulin Sales by Region (2025-2030) & (K Unit)
Table 38. Asia Pacific Biosimilar Insulin Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Biosimilar Insulin Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Biosimilar Insulin Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Biosimilar Insulin Sales by Country (2019-2024) & (K Unit)
Table 42. Latin America Biosimilar Insulin Sales by Country (2025-2030) & (K Unit)
Table 43. Latin America Biosimilar Insulin Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Biosimilar Insulin Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Biosimilar Insulin Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Biosimilar Insulin Sales by Country (2019-2024) & (K Unit)
Table 47. Middle East & Africa Biosimilar Insulin Sales by Country (2025-2030) & (K Unit)
Table 48. Middle East & Africa Biosimilar Insulin Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Biosimilar Insulin Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Biosimilar Insulin Sales (K Unit) by Type (2019-2024)
Table 51. Global Biosimilar Insulin Sales (K Unit) by Type (2025-2030)
Table 52. Global Biosimilar Insulin Sales Market Share by Type (2019-2024)
Table 53. Global Biosimilar Insulin Sales Market Share by Type (2025-2030)
Table 54. Global Biosimilar Insulin Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Biosimilar Insulin Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Biosimilar Insulin Revenue Market Share by Type (2019-2024)
Table 57. Global Biosimilar Insulin Revenue Market Share by Type (2025-2030)
Table 58. Global Biosimilar Insulin Price (US$/Unit) by Type (2019-2024)
Table 59. Global Biosimilar Insulin Price (US$/Unit) by Type (2025-2030)
Table 60. Global Biosimilar Insulin Sales (K Unit) by Distribution Channel (2019-2024)
Table 61. Global Biosimilar Insulin Sales (K Unit) by Distribution Channel (2025-2030)
Table 62. Global Biosimilar Insulin Sales Market Share by Distribution Channel (2019-2024)
Table 63. Global Biosimilar Insulin Sales Market Share by Distribution Channel (2025-2030)
Table 64. Global Biosimilar Insulin Revenue (US$ Million) by Distribution Channel (2019-2024)
Table 65. Global Biosimilar Insulin Revenue (US$ Million) by Distribution Channel (2025-2030)
Table 66. Global Biosimilar Insulin Revenue Market Share by Distribution Channel (2019-2024)
Table 67. Global Biosimilar Insulin Revenue Market Share by Distribution Channel (2025-2030)
Table 68. Global Biosimilar Insulin Price (US$/Unit) by Distribution Channel (2019-2024)
Table 69. Global Biosimilar Insulin Price (US$/Unit) by Distribution Channel (2025-2030)
Table 70. Eli Lilly Corporation Information
Table 71. Eli Lilly Description and Business Overview
Table 72. Eli Lilly Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. Eli Lilly Biosimilar Insulin Product
Table 74. Eli Lilly Recent Developments/Updates
Table 75. Sanofi Corporation Information
Table 76. Sanofi Description and Business Overview
Table 77. Sanofi Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. Sanofi Biosimilar Insulin Product
Table 79. Sanofi Recent Developments/Updates
Table 80. Gan&Lee Corporation Information
Table 81. Gan&Lee Description and Business Overview
Table 82. Gan&Lee Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Gan&Lee Biosimilar Insulin Product
Table 84. Gan&Lee Recent Developments/Updates
Table 85. Tonghua Dongbao Corporation Information
Table 86. Tonghua Dongbao Description and Business Overview
Table 87. Tonghua Dongbao Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Tonghua Dongbao Biosimilar Insulin Product
Table 89. Tonghua Dongbao Recent Developments/Updates
Table 90. United Laboratory Corporation Information
Table 91. United Laboratory Description and Business Overview
Table 92. United Laboratory Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. United Laboratory Biosimilar Insulin Product
Table 94. United Laboratory Recent Developments/Updates
Table 95. Geropharm Corporation Information
Table 96. Geropharm Description and Business Overview
Table 97. Geropharm Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Geropharm Biosimilar Insulin Product
Table 99. Geropharm Recent Developments/Updates
Table 100. Biocon Corporation Information
Table 101. Biocon Description and Business Overview
Table 102. Biocon Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Biocon Biosimilar Insulin Product
Table 104. Biocon Recent Developments/Updates
Table 105. Wockhardt Corporation Information
Table 106. Wockhardt Description and Business Overview
Table 107. Wockhardt Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. Wockhardt Biosimilar Insulin Product
Table 109. Wockhardt Recent Developments/Updates
Table 110. Key Raw Materials Lists
Table 111. Raw Materials Key Suppliers Lists
Table 112. Biosimilar Insulin Distributors List
Table 113. Biosimilar Insulin Customers List
Table 114. Biosimilar Insulin Market Trends
Table 115. Biosimilar Insulin Market Drivers
Table 116. Biosimilar Insulin Market Challenges
Table 117. Biosimilar Insulin Market Restraints
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Biosimilar Insulin
Figure 2. Global Biosimilar Insulin Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Biosimilar Insulin Market Share by Type in 2023 & 2030
Figure 4. Biosimilar Insulin Glargine Product Picture
Figure 5. Biosimilar Insulin Lispro Product Picture
Figure 6. Other Product Picture
Figure 7. Global Biosimilar Insulin Market Value Comparison by Distribution Channel (2024-2030) & (US$ Million)
Figure 8. Global Biosimilar Insulin Market Share by Distribution Channel in 2023 & 2030
Figure 9. Hospital
Figure 10. Retail Pharmacy
Figure 11. Others
Figure 12. Global Biosimilar Insulin Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Biosimilar Insulin Market Size (2019-2030) & (US$ Million)
Figure 14. Global Biosimilar Insulin Sales (2019-2030) & (K Unit)
Figure 15. Global Biosimilar Insulin Average Price (US$/Unit) & (2019-2030)
Figure 16. Biosimilar Insulin Report Years Considered
Figure 17. Biosimilar Insulin Sales Share by Manufacturers in 2023
Figure 18. Global Biosimilar Insulin Revenue Share by Manufacturers in 2023
Figure 19. The Global 5 and 10 Largest Biosimilar Insulin Players: Market Share by Revenue in 2023
Figure 20. Biosimilar Insulin Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 21. Global Biosimilar Insulin Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 22. North America Biosimilar Insulin Sales Market Share by Country (2019-2030)
Figure 23. North America Biosimilar Insulin Revenue Market Share by Country (2019-2030)
Figure 24. United States Biosimilar Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 25. Canada Biosimilar Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 26. Europe Biosimilar Insulin Sales Market Share by Country (2019-2030)
Figure 27. Europe Biosimilar Insulin Revenue Market Share by Country (2019-2030)
Figure 28. Germany Biosimilar Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. France Biosimilar Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. U.K. Biosimilar Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Italy Biosimilar Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Russia Biosimilar Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. Asia Pacific Biosimilar Insulin Sales Market Share by Region (2019-2030)
Figure 34. Asia Pacific Biosimilar Insulin Revenue Market Share by Region (2019-2030)
Figure 35. China Biosimilar Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. Japan Biosimilar Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. South Korea Biosimilar Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. India Biosimilar Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Australia Biosimilar Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. China Taiwan Biosimilar Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Southeast Asia Biosimilar Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Latin America Biosimilar Insulin Sales Market Share by Country (2019-2030)
Figure 43. Latin America Biosimilar Insulin Revenue Market Share by Country (2019-2030)
Figure 44. Mexico Biosimilar Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Brazil Biosimilar Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Argentina Biosimilar Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Middle East & Africa Biosimilar Insulin Sales Market Share by Country (2019-2030)
Figure 48. Middle East & Africa Biosimilar Insulin Revenue Market Share by Country (2019-2030)
Figure 49. Turkey Biosimilar Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Saudi Arabia Biosimilar Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. UAE Biosimilar Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Global Sales Market Share of Biosimilar Insulin by Type (2019-2030)
Figure 53. Global Revenue Market Share of Biosimilar Insulin by Type (2019-2030)
Figure 54. Global Biosimilar Insulin Price (US$/Unit) by Type (2019-2030)
Figure 55. Global Sales Market Share of Biosimilar Insulin by Distribution Channel (2019-2030)
Figure 56. Global Revenue Market Share of Biosimilar Insulin by Distribution Channel (2019-2030)
Figure 57. Global Biosimilar Insulin Price (US$/Unit) by Distribution Channel (2019-2030)
Figure 58. Biosimilar Insulin Value Chain
Figure 59. Biosimilar Insulin Production Process
Figure 60. Channels of Distribution (Direct Vs Distribution)
Figure 61. Distributors Profiles
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
